In vitro Anti‐tumor Activity of Anti‐c‐erbB‐2 × Anti‐CD3ɛ Bifunctional Monoclonal Antibody

With the aim of developing an effective cancer immunotherapy for common epithelial cancer, a new class of bifunctional antibody (BFA) was developed; one arm of this BFA recognized c‐erbB‐2 gene product, and the other arm recognized CD3ɛ, a T‐cell specific surface antigen. Application of this BFA wit...

Full description

Saved in:
Bibliographic Details
Published in:Cancer science 1992-06, Vol.83 (6), p.563-567
Main Authors: Sugiyama, Yoshihiro, Aihara, Miki, Shibamori, Masafumi, Deguchi, Kyohei, Imagawa, Kenichi, Kikuchi, Mikio, Momota, Hiroshi, Azuma, Takachika, Okada, Hidechika, Alper, Özge, Hitomi, Jiro, Yamaguchi, Ken
Format: Article
Language:English
Subjects:
Anti‐CD3ɛ
Anti‐c‐erbB‐2
Bifunctional antibody
Breast cancer
Cancer immunotherapy
Cell surface
ErbB protein
Immunotherapy
Key words
Lymphocytes
Monoclonal antibodies
Monoclonal antibody
Peripheral blood
Rapid Communication
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:With the aim of developing an effective cancer immunotherapy for common epithelial cancer, a new class of bifunctional antibody (BFA) was developed; one arm of this BFA recognized c‐erbB‐2 gene product, and the other arm recognized CD3ɛ, a T‐cell specific surface antigen. Application of this BFA with human peripheral blood lymphocytes exhibited specific anti‐tumor activity in vitro on a breast tumor cell line, ZR‐75–1, which expressed abundant c‐erbB‐2 gene product on its cell surface. These results indicate that BFA recognizing an oncogene product on cell surface is a potential new agent for cancer immunotherapy.
ISSN:0910-5050
1347-9032
1349-7006
1876-4673
DOI:10.1111/j.1349-7006.1992.tb00126.x